Pharmaceutical

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.

Dec 18, 2023 - 10:51
CymaBay seeks FDA approval for primary biliary cholangitis therapy
CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.
Read the original article

Tags:

Previous Article

Biocytogen and Ona enter cancer ADC development deal

Next Article

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Key House Republican escalates rhetoric against PBMs

STAT+: Key House Republican escalates rhetoric against ...

Jun 14, 2023

Opinion: What the hospital-at-home movement tells us about igniting innovation in health care

Opinion: What the hospital-at-home movement tells us ab...

Aug 21, 2023

Who’s acquiring who? Virtual care M&A activity in the pharmaceutical industry increased by 100% in Q1 2023

Who’s acquiring who? Virtual care M&A activity in the p...

May 28, 2023